Day: May 18, 2020

SELSKABSMEDDELELSE NR. 13 – 18. MAJ 2020OPDATERING: Grundet Covid-19 situationen og det gældende forsamlingsforbud udskød NORDEN den årlige generalforsamling (selskabsmeddelelse nr. 11). NORDEN har nu fastsat ny dato for afholdelse af generalforsamling.Dampskibsselskabet NORDEN A/S har fastlagt følgende datoer i 2020 for års- og delårsrapporter samt generalforsamling m.v.: Med venlig hilsenDampskibsselskabet NORDEN A/SJan RindboAdm.direktørYderligere oplysninger:Martin Badsted, Finansdirektør, tlf.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tlf.: +45 3273 0624Vedhæftet filNr. 13 – Opdateret finanskalender 2020

18 May 2020G4S plc(the ‘Company’)Disclosure of rights attached to equity sharesIn compliance with Listing Rule 9.2.6E (disclosure of rights attached to equity shares), the Company has forwarded to the FCA for publication a copy of its articles of association, which sets out the principal rights and restrictions attached to its ordinary shares.A copy of the articles of association has been submitted to the National Storage Mechanism and will shortly be available for inspection.Notes to Editors:G4S is the leading global security company, specialising in the provision of security services and solutions to customers. Our mission is to create material, sustainable value for our customers and shareholders by being the supply partner of choice in all our markets.G4S is quoted on the London Stock Exchange and has a secondary stock exchange listing...

Westport, CT, May 18, 2020 (GLOBE NEWSWIRE) —Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task ForceRandomized, double blind, placebo-controlled clinical trial to be conducted in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug (IND) application. The FDA informed ViralClear that it may proceed with a proposed...

HOUSTON, May 18, 2020 (GLOBE NEWSWIRE) — C-Bond Systems, Inc., (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, has reported an operational update focused on the recent establishment of two new divisions focused on its core intellectual property to serve existing markets with an evolving nano-product portfolio, as well as reported financial results for the first quarter ended March 31, 2020.First Quarter 2020 and Subsequent Operational HighlightsEstablished C-Bond Transportation Solutions, anchored by our patented C-Bond NanoShield™ product line, and focused on sales efforts to fleet operators, new car dealers, service providers, warranty and F&I companies, and windshield OEMs, and evolving to address the needs of the broader transportation market.Established C-Bond Safety Solutions, anchored by...

Continued annual revenue growthNumber of commercial CDA (cancer differentiation analysis)-based tests increased 26.0% year-on-yearContinued to gain customers and increase the acceptance of our cancer risk assessment testsSAN JOSE, Calif., May 18, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio,” “we” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its financial results for the year ended December 31, 2019 in its annual report on Form 20-F (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2020.Full Year 2019 Financial HighlightsNumber of commercial CDA-based tests reached a record high of 52,428 completed in 2019, an increase of 26.0%...

MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.“With the CCR2 inhibitor CCX140 we desired to help people with FSGS,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Regrettably the data observed in the dose-ranging Phase II LUMINA-1...

ST. LOUIS, May 18, 2020 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced the hiring of two experienced Managing Directors in its Investment Banking division. Alex Rohan joins Miller Buckfire, Stifel’s restructuring unit, and Greg Urban joins the Stifel Diversified Industrials Group, with a specific focus on the automotive sector. Both have a broad range of experience and expertise, including in restructuring, which is in high demand due to economic fallout from the COVID-19 crisis.Alex Rohan brings more than 25 years of investment banking, legal, and financial advisory experience, most of which has involved corporate restructurings. During that time, he advised on approximately 125 transactions, representing more than $150 billion in liabilities. Most recently, he was a Senior Managing Director in the Corporate...

TULSA, OK, May 18, 2020 (GLOBE NEWSWIRE) — Laredo Petroleum, Inc. (NYSE: LPI) (“Laredo” or “the Company”), today announced the appointment of William Albrecht as independent Chairman of the Board of Directors (the “Board”), succeeding Randy Foutch upon the expiration of Mr. Foutch’s term on May 14, 2020. Mr. Albrecht, currently an independent member of the Board, will continue to serve on the Compensation Committee and Nominating and Corporate Governance Committee.“Bill’s appointment as Chairman fulfills Laredo’s prior commitment to separate the roles of Chairman and Chief Executive Officer and name an independent Chairman,” stated Dr. Bill Scoggins, Chair of the Nominating and Corporate Governance Committee. “His extensive energy industry background and leadership...

LAS VEGAS, NV, May 18, 2020 (GLOBE NEWSWIRE) — Ionix Technology, Inc. (OTCQB: IINX), (“Ionix Technology”, “IINX” or “the Company”), a business aggregator in photoelectric display and smart energy fields, announced its financial results for the three months ended March 31, 2020.Third Quarter 2020 Financial Highlights:Total revenues were $2,752,170 and $2,894,802 respectively for the three months ended March 31, 2020 and 2019. Gross profit was $245,652 and $623,422, respectively for the three months ended March 31, 2020 and 2019. During the three months ended March 31, 2020 and 2019 net income (loss) was $(636,222) and $21,064, respectively.“From early February to the end of March, we closed all factories to limit the spread of COVID-19. The shutdown of business affected the operational and financial...